Home / Health / New COPD Drug Shows Promising Trial Results
New COPD Drug Shows Promising Trial Results
8 Sep
Summary
- Tozorakimab drug reduced COPD symptoms in clinical trials.
- The drug is a first biologic option for low eosinophil counts.
- FDA granted priority review for the new COPD treatment.
New clinical trial results indicate that AstraZeneca's experimental drug, tozorakimab, shows significant promise in alleviating chronic obstructive pulmonary disease (COPD) symptoms for current and former smokers. The medication, a biologic drug, demonstrated efficacy across a broad patient group, including those with varying blood eosinophil counts.
In two separate trials, patients receiving tozorakimab injections experienced notable reductions in moderate and severe COPD exacerbations, ranging from 29% to 34% compared to placebo. The drug was found to be well-tolerated, with no significant side effects reported beyond injection site reactions.
Tozorakimab targets interleukin-33, a protein that promotes inflammation in conditions like COPD. The U.S. Food and Drug Administration has granted priority review for tozorakimab as an add-on maintenance treatment for adults with COPD, signaling an expedited review process.
COPD affects nearly 16 million U.S. adults and is a leading cause of death. While tobacco smoke is a primary cause, a significant number of patients have never smoked, highlighting the need for diverse treatment options.
